Axpaxli FDA Path Cleared
Ocular Therapeutix Receives FDA Alignment for Axpaxli Wet AMD Drug NDA, Aims for 2027 Launch
Key Points
Ocular said SOL-R will remain masked through Week 96, and it plans an interim SOL-R safety analysis in Q4 2026 designed to compile safety data from more than 300 patients across SOL-1 and SOL-R—consistent with FDA requirements.
For its diabetic retinopathy program, Ocular is prioritizing HELIOS-3 as a potential single registrational trial evaluating AXPAXLI dosing every 12 months.
Ocular provided additional SOL-1 context: the SOL-1 trial completed randomization of 344 treatment-naïve patients with wet AMD in December 2024, and in February 2026 it reported 74.1% of patients in the AXPAXLI arm maintained vision at Week 36 versus the aflibercept arm (superiority primary endpoint p=0.0006).
Nasdaq trading mechanics: after the June 17 announcement, Ocular’s shares were set to recommence at 9:15 a.m. ET following a scheduled quotation resumption at 9:10 a.m. ET, according to the company’s Nasdaq notice.
Market reaction detail: after the FDA-alignment news, shares rose 3% to $9.22 ahead of the opening bell, per MarketWatch.
Ocular Therapeutix said the U.S. FDA is aligned with its plan to file a New Drug Application for Axpaxli, a once-or-twice-yearly eye implant for wet age-related macular degeneration, with submission expected in Q4 2026 and a potential commercial launch in 2027, according to Morningstar. Shares rose 3% to $9.22 ahead of the opening bell on June 17 before pulling back after the company's Investor Day later that afternoon.
CEO Dr. Pravin Dugel called Axpaxli the "first and only investigational product" to show superiority over an approved anti-VEGF drug in a landmark trial. At Week 36, 74.1% of Axpaxli patients maintained vision versus 56.6% on aflibercept — a 17.5-point gap with a p-value of 0.0006, per GuruFocus.
What Goes Into the NDA Package and When
The NDA will rely on two sets of data: Week 52 efficacy and safety results from the SOL-1 trial, plus interim safety data from the ongoing SOL-R trial. SOL-1 enrolled 344 treatment-naïve wet AMD patients and completed randomization in December 2024. At Week 52, 65.9% of Axpaxli patients maintained vision versus 44.8% on aflibercept — a 21.1-point gap with p<0.0001, according to Ophthalmology Times.
The FDA requires safety data from more than 300 patients across both SOL-1 and SOL-R. Ocular plans an interim SOL-R safety analysis in Q4 2026 to meet that bar, per StreetInsider. Critically, SOL-R efficacy data will not be part of the initial NDA — a move analysts view as a smart shortcut that avoids waiting for the full 2028 trial readout.
505(b)(2) Pathway Could Shorten FDA Review by Two Months
Ocular is using the 505(b)(2) regulatory pathway, which lets a company reference existing data from a previously approved drug. Here, Axpaxli can lean on the safety and efficacy record of aflibercept. That approach is expected to cut the FDA review timeline by roughly 60 days, according to StreetInsider.
A pre-NDA meeting with the FDA is expected in Q3 2026 before the formal submission. The company reached alignment with the FDA after a Type C meeting held in May 2026. If the NDA is filed on schedule and approved, Axpaxli could reach the market in 2027 — reducing patient injection frequency from up to 12 times per year to once or twice annually, per Morningstar.
SOL-R Redesigned to Challenge Eylea HD in 2028
SOL-R will stay masked — meaning results stay hidden from researchers and investors — all the way through Week 96. The trial's key secondary endpoint now pits Axpaxli against aflibercept 8mg (Eylea HD, made by Regeneron) every six months. Topline results from that comparison are expected in Q1 2028, per GuruFocus.
Ocular frames the redesign as a bid for a "best-in-disease" label against the highest-dose competitor on the market. Some investors pushed back, viewing the 2028 wait as a de facto delay in proving long-term repeat-dosing performance. That tension likely contributed to the stock's afternoon decline on Investor Day, according to GuruFocus.
Diabetic Retinopathy Program Trimmed to One Pivotal Trial
Ocular also announced it is streamlining its diabetic retinopathy pipeline. The company is now betting on HELIOS-3 as a single registrational trial, evaluating Axpaxli dosing every 12 months. HELIOS-3 enrolled its first patient in November 2025, according to BioSpace. Relying on one trial lowers costs but raises the stakes — a single failure could sink the entire program.
On the financial side, Ocular's market cap stands near $1.96 billion, though its Price-to-Sales ratio of 33.86 signals that investors have already priced in substantial growth. Insiders sold about $0.4 million in stock over the past three months. Analyst price targets still range from $18 to $34, well above the current share price, per GuruFocus.
Sentiment
Mostly PositivePublishers
13
Articles
36
Reach
49
